Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Gastric Cancer Drugs Market Size From 2025 to 2034?

There has been a swift expansion of the market size for gastric cancer drugs in the past few years. This market is projected to increase from $4.41 billion in 2024 to around $4.9 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.2%. Factors such as rising pharmaceutical R&D spending, escalated healthcare expenses, robust economic growth in developing markets and a skyrocketing elderly population have contributed to the historical growth of this market.

In the next few years, the market for gastric cancer drugs is projected to experience rapid expansion. The anticipation is for a growth to $7.35 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.7%. This growth in the forecasted period can be credited to a rise in the incidence rate of gastric cancer, a solid pipeline of medications, increased healthcare expenditure, and updated FDA guidelines to assist the development of biologics drugs. The period also sees an uptick in acquisitions and partnerships, an aging population, and the progression of strong drug pipelines. Major trends within this period involve strategic collaborations and agreements to expand product ranges, partnerships with other businesses or governmental entities, an increased number of pipeline studies conducted for the development of gastric cancer drugs, investments in AI to lower R&D expenses, the progression of next-gen biologics, and the application of CRISPR-cas9 technology in creating new drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Are the Core Growth Drivers Propelling the Gastric Cancer Drugs Market Forward?

The rise in obesity rates and the number of smokers has resulted in a heightened number of gastric cancer cases. Unhealthy dietary practices and tobacco consumption heighten the risk of developing stomach cancer. For example, predictions from the Government Digital Service, a UK-based government body, in May 2023 indicated that in England, 25.9% of people (aged 18 and over) were obese in 2022–2022, marking an increase from the previous 25.2%. This surge in gastric cancer incidents is expected to propel the growth of the gastric cancer drugs market.

What Segment Types Define the Gastric Cancer Drugs Market Structure?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Emerging Trends that Are Influencing theGastric Cancer Drugs Industry Evolution?

Numerous businesses in the gastric cancer drugs industry are pioneering novel products like anti-PD-1 therapies in order to amplify the effectiveness of treatments and betterment of patients. Anti-PD-1 treatment is an immunotherapy that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. For example, in November 2023, Merck & Co., Inc., a pharmaceutical firm based in the US, was given the green light by the Food and Drug Administration (FDA), a federal agency in the US responsible for ensuring public health, for KEYTRUDA (pembrolizumab). KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy employed to treat gastric cancer. Specifically, it’s meant for initial treatment of patients suffering from locally advanced irreparable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This treatment is intended for use in combination with trastuzumab, as well as fluoropyrimidine- and platinum-containing chemotherapy, and has been granted accelerated approval based on tumor response rate and the duration of said response.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What Is the Definition of the Gastric Cancer Drugs Market?

Gastric cancer drugs refer to anti-cancer medications that are taken orally as pills or are injected into a vein (via an IV line or central venous catheter). This treatment is effective for cancer that has spread to organs other than those where it originated since these medications penetrate the bloodstream and reach every part of the body.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model